Drug reps will promote Avandia (rosiglitazone) as more effective than metformin for initial therapy of type 2 diabetes

January 2007

Drug reps will promote Avandia (rosiglitazone) as more effective than metformin for initial therapy of type 2 diabetes.

They're citing a new study that suggests patients maintain control longer with rosiglitazone than with metformin or glyburide.

You'll hear that 5-year treatment failures are 32% higher with metformin and 63% higher with glyburide compared to rosiglitazone.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote